Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
72 studies found for:    Paraneoplastic Syndromes
Show Display Options
RSS Create an RSS feed from your search for:
Paraneoplastic Syndromes
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Immunotherapy of the Paraneoplastic Syndromes
Condition: Paraneoplastic Syndromes
Intervention: Drug: Tacrolimus
2 Completed Studies of Neurological Paraneoplastic Syndromes
Condition: Paraneoplastic Neurologic Degenerations (PNDs)
Intervention:
3 Recruiting The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
Condition: Paraneoplastic Syndromes
Intervention:
4 Recruiting Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia
Condition: Hypophosphatemia
Intervention:
5 Unknown  Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome
Condition: Opsoclonus-myoclonus Syndrome
Intervention:
6 Active, not recruiting Immunotherapy and Paraneoplastic Neurological Syndromes
Condition: Paraneoplastic Neurological Syndromes
Intervention: Drug: Immunoglobulin
7 Completed
Has Results
One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
Conditions: Osteoporosis;   Humoral Hypercalcemia of Malignancy;   Hyperparathyroidism
Intervention: Drug: PTHrP (1-36)
8 Unknown  Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone
Conditions: Breast Cancer;   Hypercalcemia of Malignancy;   Metastatic Cancer;   Musculoskeletal Complications;   Pain
Interventions: Drug: zoledronic acid;   Procedure: quality-of-life assessment
9 Unknown  Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
Conditions: Breast Cancer;   Hypercalcemia of Malignancy;   Metastatic Cancer
Interventions: Drug: ibandronate sodium;   Drug: zoledronic acid;   Drug: Zolendronic Acid
10 Withdrawn S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
Conditions: Breast Cancer;   Hypercalcemia of Malignancy;   Metastatic Cancer;   Pain
Interventions: Drug: ibandronate;   Drug: zoledronate;   Procedure: quality-of-life assessment
11 Completed Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
Conditions: Breast Cancer;   Hypercalcemia of Malignancy;   Metastatic Cancer;   Pain
Interventions: Biological: monoclonal antibody CAL;   Drug: zoledronic acid
12 Completed Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
Conditions: Hypercalcemia of Malignancy;   Lung Cancer;   Metastatic Cancer;   Pain;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: zoledronic acid;   Procedure: quality-of-life assessment
13 Completed Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Condition: Congenital Myasthenic Syndrome
Intervention: Drug: Albuterol
14 Available Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine
15 Available Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4 DAP
16 Unknown  Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Conditions: Lambert-Eaton Myasthenic Syndrome;   Eaton-Lambert Myasthenic Syndrome
Interventions: Drug: 3,4-DAP;   Drug: 3,4-DAP Taper to Placebo
17 Available Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4-Diaminopyridine
18 Recruiting 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome
Interventions: Drug: 3,4-DIAMINOPYRIDINE;   Drug: 3,4-Diaminopyridine
19 Completed A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate;   Drug: Placebo
20 No longer available Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 DAP

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.